MyMD Pharmaceuticals Enrolls First Person in Phase 2 Clinical Trial of MYMD-1 as a Treatment for Delaying Aging and also Increasing Healthy And Balanced Life-span

MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals (” MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy life expectancy, today introduced that the first patient has been signed up in the Business’s Phase 2 clinical test of lead prospect MYMD-1, an oral immune regulatory authority drug, as a therapy for postponing aging as well as increasing healthy and balanced life expectancy.

The main endpoint for the Phase 2 double-blind, placebo-controlled scientific trial is to achieve a decrease in the flowing levels of (TNF-α), lump necrosis factor receptor I (TNFRI) as well as IL-6. TNF-α as well as IL-6 are the healthy proteins in the body that create swelling and aid trigger the procedure of aging. The second procedures of the trial will be the safety, tolerability, as well as pharmacokinetics in this population of individuals.

” In a Stage 1 clinical test of MYMD-1, we showed the medicine’s statistically considerable effectiveness in minimizing levels of TNF-α, a key player in triggering pathological aging, in the blood. The FDA has approved TNF-α reduction as the key endpoint for our Phase 2 study, which our team believe placements us well for a successful Phase 2 result,” stated Chris Chapman, M.D., Head Of State, Supervisor and Principal Medical Policeman of MyMD. “The initiation of client registration in this research study developments our mission to reduce the aging procedure, stop loss of muscle mass tissue in aging, restriction frailty, as well as expand healthy life expectancy.”

MyMD has actually specified that there are no FDA-approved drugs for dealing with aging problems as well as prolonging healthy life expectancy human beings, a market expected to be at least $600 billion by 20251 according to a significant investment bank. TNF-α blockers are the most prescribed medications by profits, an international market of about $40 billion per year,2 as well as, according to Nature Aging journal,3 a stagnation in maturing that would certainly raise life expectancy by one year is worth $38 trillion and also by one decade is worth $367 trillion.

In addition to aging, MYMD-1’s distinct activity in managing the body immune system as well as dealing with chronic swelling is being developed for the treatment of autoimmune condition, including rheumatoid arthritis (RA), several sclerosis (MS), diabetes mellitus, and also inflammatory digestive tract illness.

” We intend to start writing protocols for a Stage 2 pilot research of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman kept in mind. “The increasing occurrence of rheumatoid joint inflammation and also other autoimmune as well as inflammatory illness are driving need for TNF inhibitors like MYMD-1, and we believe our orally administered medication with really reduced toxicity would be turbulent to the $60 billion market for RA if accepted by the FDA for this indicator.”

Rheumatoid joint inflammation affects about 40 million individuals globally.4.

Regarding MYMD-1.

Initially developed for autoimmune conditions, MYMD-1’s main objective is to reduce the aging procedure, stop sarcopenia and also frailty, and prolong healthy and balanced life expectancy. Because it can go across the blood-brain obstacle as well as access to the main nervous system (CNS), MYMD-1 is also placed to be a feasible therapy for brain-related disorders. Its mechanism of activity and efficiency in illness consisting of numerous sclerosis (MS) and also thyroiditis have actually been studied with partnerships with several scholastic institutions. MYMD-1 is additionally showing assurance in pre-clinical researches as a potential treatment for article- COVID-19 problems and as an anti-fibrotic and also anti-proliferation restorative.

MYMD-1 has actually revealed efficiency in pre-clinical studies in regulating the immune system by carrying out as a discerning inhibitor of lump death factor-alpha (TNF-α), a motorist of chronic inflammation. Unlike other therapies, MYMD-1 has actually been shown in these pre-clinical studies to uniquely block TNF-α when it comes to be overactivated in autoimmune illness as well as cytokine storms, yet not block it from doing its typical work of being an initial responder to any type of routine sort of moderate infection. MYMD-1’s simplicity of oral dosing is one more differentiator compared to currently readily available TNF-α blockers, all of which need shipment by shot or infusion. No authorized TNF inhibitor has ever been dosed orally. In addition, the medicine is not immunosuppressive and also has not been shown to create the major negative effects typical with typical therapies that treat swelling.

About MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a scientific stage pharmaceutical firm dedicated to prolonging healthy life-span, is focused on establishing 2 novel therapeutic platforms that deal with the root causes of illness instead of only dealing with the symptoms. MYMD-1 is a medicine system based upon a clinical phase small particle that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, boost long life, and treat autoimmune diseases as well as COVID-19- linked anxiety. The Company’s second medicine platform, Supera-CBD, is being created to treat persistent discomfort, dependency as well as epilepsy. Supera-CBD is an unique synthetic derivative of cannabidiol (CBD) and also is being established to deal with as well as improve upon the rapidly expanding CBD market, that includes both FDA approved medications and CBD items not presently managed as medicines. To find out more, check out www.mymd.com.